Table 2. Evaluation of alternative m/p-substituents.
| ID |
|
EC50(Nurr1) (max. activation) a |
|---|---|---|
| 19 |
|
inactive (10 μM) |
| 20 |
|
1.1±0.2 μM (1.4±0.1-fold) |
| 21 |
|
inactive (10 μM) |
| 22 |
|
inactive (10 μM) |
| 23 |
|
inactive (10 μM) |
| 24 |
|
0.26±0.04 μM (1.6±0.1-fold) |
| 25 |
|
0.5±0.2 μM (1.4±0.1-fold) |
| 26 |
|
0.04±0.01 μM (1.5±0.1-fold) |
| 27 |
|
0.32±0.08 μM (1.4±0.1-fold) |
| 28 |
|
0.7±0.1 μM (1.9±0.1-fold) |
| 29 |
|
0.07±0.02 μM (1.5±0.1-fold) |
| 30 |
|
0.9±0.2 μM (1.5±0.1-fold) |
| 31 |
|
0.2±0.1 μM (1.5±0.1-fold) |
Nurr1 modulation was determined in a Gal4-Nurr1 hybrid reporter gene assay. Max. activation refers to the maximum effect vs. 0.1% DMSO control. Data are the mean±SD; n≥3.